ORMP
Oramed Pharmaceuticals
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: ORMP
- PE Ratio
The current PE ratio for Oramed Pharmaceuticals stock as of Jun 2, 2026 is 1.36. This is calculated based on the TTM EPS of $2.65 and the stock price of $3.6 per share.
ORMP PE ratio history
The average historical PE ratio of Oramed Pharmaceuticals for the last three years is 8.66. The current P/E ratio of 1.36 is 84% lower than the historical average. Looking back at the last three years, ORMP's PE ratio peaked in the Sep 2024 quarter at 22.18, when the price was $2.44 and the EPS was $0.11. The lowest point was in the Mar 2026 quarter, when it reached 1.28 with a price of $3.4 and an EPS of $2.65.
Oramed Pharmaceuticals PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 1.86 | N/A | $2.85 | $1.53 |
| 2024 | N/A | N/A | $2.42 | -$0.48 |
| 2023 | 16.5 | N/A | $2.31 | $0.14 |
| 2022 | N/A | N/A | $12.03 | -$0.94 |
| 2021 | N/A | N/A | $19.68 | -$0.78 |
| 2020 | N/A | N/A | $3.49 | -$0.56 |
| 2019 | N/A | N/A | $3.32 | -$0.82 |
| 2018 | N/A | N/A | $4.95 | -$0.86 |
| 2017 | N/A | N/A | $8.65 | -$0.79 |
| 2016 | N/A | N/A | $7.21 | -$0.87 |
| 2015 | N/A | N/A | $5.62 | -$0.67 |
| 2014 | N/A | N/A | $10.14 | -$0.62 |
| 2013 | N/A | N/A | $7.29 | -$0.59 |
| 2012 | N/A | N/A | $3.84 | -$0.57 |
| 2011 | N/A | N/A | $3.12 | -$0.24 |
Oramed Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 1.28 | -31.18% | $3.4 | $2.65 |
| Dec 2025 | 1.86 | -27.34% | $2.85 | $1.53 |
| Sep 2025 | 2.56 | N/A | $2.64 | $1.03 |
| Jun 2025 | N/A | N/A | $2.25 | -$0.61 |
| Mar 2025 | N/A | N/A | $2.14 | -$0.71 |
| Dec 2024 | N/A | N/A | $2.42 | -$0.48 |
| Sep 2024 | 22.18 | 340.08% | $2.44 | $0.11 |
| Jun 2024 | 5.04 | -55.12% | $2.57 | $0.51 |
| Mar 2024 | 11.23 | -31.94% | $2.92 | $0.26 |
| Dec 2023 | 16.5 | N/A | $2.31 | $0.14 |
| Sep 2023 | N/A | N/A | $2.61 | -$0.41 |
| Jun 2023 | N/A | N/A | $3.58 | -$0.51 |
| Mar 2023 | N/A | N/A | $2.18 | -$0.75 |
| Dec 2022 | N/A | N/A | $12.03 | -$0.94 |
| Sep 2022 | N/A | N/A | $6.48 | -$1.03 |
ORMP Price vs fair value
ORMP average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
ORMP's current PE ratio is lower than its 3, 5 and 10-year averages.
PE comparison
With a price to earnings (P/E) of 1.36, ORMP ranks lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 23.23, Oramed Pharmaceuticals's price to earnings (P/E) is 94% lower.
ORMP PE vs peers
ORMP's PE ratio stands lower than its peer stock PLX.
| Stock name | PE ratio | Market cap |
|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 1.38 | $149.79M |
| PLX Protalix BioTherapeutics Inc | 10.32 | $157.92M |
| RARE Ultragenyx Pharmaceutical Inc | N/A | $2.21B |
| LXRX Lexicon Pharmaceuticals Inc | N/A | $819.54M |
Frequently asked questions
What is Oramed Pharmaceuticals's PE ratio?
The price to earnings ratio for ORMP stock is 1.36 as of Jun 2, 2026.
What is the 3-year average PE ratio for Oramed Pharmaceuticals (ORMP)?
Over the last 3 years, the average price to earnings ratio for ORMP stock is 8.66.
What is the 5-year average PE ratio for Oramed Pharmaceuticals (ORMP)?
Over the last 5 years, the average price to earnings ratio for ORMP stock is 8.66.
What is the highest PE ratio for ORMP?
The highest quarterly PE ratio in the last three years has been 22.18 and it was in the Sep 2024 quarter.
How does the current PE ratio for ORMP compare to its historical average?
The current PE ratio of ORMP is 84% lower than the 3-year historical average.
Why is Oramed Pharmaceuticals's PE ratio so low?
A company with a lower PE ratio may indicate that the market has lower growth expectations for the company's future earnings.
How is ORMP's PE ratio calculated (Oramed Pharmaceuticals PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Jun 2, 2026), Oramed Pharmaceuticals's share price is $3.6. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $2.65. Therefore, Oramed Pharmaceuticals's PE ratio for today is 1.36. PE RATIO(1.36) = STOCK PRICE($3.6) / TTM EPS($2.65)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.